Phibro Animal Health (PAHC) vs Ultragenyx Pharmaceutical (RARE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Phibro Animal Health (PAHC) has outperformed Ultragenyx Pharmaceutical (RARE) over the past year, gaining 3.0% versus a loss of 50.5%. Over five years, PAHC leads with a +75.7% price change compared with -80.9% for RARE. Phibro Animal Health is the larger company by market cap ($1.56 billion vs $1.53 billion), about 1.0 times the size, while Ultragenyx Pharmaceutical is growing revenue faster (+20.2% vs +17.1%).
On valuation, Phibro Animal Health trades at a lower forward P/E (10.0x vs 22.9x for Ultragenyx Pharmaceutical). Phibro Animal Health pays a dividend yielding 1.25%, while Ultragenyx Pharmaceutical does not currently pay one. Phibro Animal Health converts more of its revenue into profit, with a net margin of 6.6% versus -85.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PAHC | RARE |
|---|---|---|
| Share price | $38.30 | $15.48 |
| Market cap | $1.56B | $1.53B |
| 1-day change | +2.41% | +1.24% |
| YTD return | +2.52% | -33.52% |
| 1-year return | +3.04% | -50.45% |
| 5-year return | +75.69% | -80.89% |
| P/E ratio (TTM) | 15.76 | — |
| Forward P/E | 9.97 | 22.87 |
| EPS (TTM) | $2.43 | $-5.82 |
| Dividend yield | 1.25% | 0.00% |
| Annual dividend | $0.48 | $0.00 |
| Revenue (latest FY) | $1.52B | $673.00M |
| Revenue growth (YoY) | +17.12% | +20.18% |
| Net income (latest FY) | $99.72M | $-575.00M |
| Gross margin | 33.76% | — |
| Operating margin | 12.81% | -79.49% |
| Net margin | 6.57% | -85.44% |
| 52-week high | $60.08 | $39.89 |
| 52-week low | $28.25 | $12.73 |
| Distance from 52-week high | -36.25% | -61.19% |
| Analyst consensus | hold | buy |
| Avg. price target upside | +14.88% | +81.20% |
| Average volume | 236.19K | 3.87M |
| Shares outstanding | 21.11M | 98.59M |
| Employees | 2,605 | 1,371 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PAHC has outperformed RARE by 53.5 percentage points over the past year.
- Phibro Animal Health offers a meaningfully higher dividend yield (1.25% vs 0.00%).
- Phibro Animal Health is more profitable, keeping 6.6 cents of every revenue dollar as net income versus -85.4 cents for Ultragenyx Pharmaceutical.
About Phibro Animal Health
PAHC stock →Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,605 employees
About Ultragenyx Pharmaceutical
RARE stock →Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,371 employees
PAHC vs RARE FAQ
Which is bigger, Phibro Animal Health or Ultragenyx Pharmaceutical?
Phibro Animal Health (PAHC) is larger, with a market capitalization of $1.56B compared with $1.53B for Ultragenyx Pharmaceutical (RARE).
Which stock has performed better over the past year, PAHC or RARE?
PAHC returned +3.04% over the past 12 months, compared with -50.45% for RARE (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Phibro Animal Health or Ultragenyx Pharmaceutical?
Phibro Animal Health pays a dividend yielding 1.25%, while Ultragenyx Pharmaceutical does not currently pay a regular dividend.
Are Phibro Animal Health and Ultragenyx Pharmaceutical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.